Waters Corporation EV/EBIT

EV/EBIT of WAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/EBIT growth rates and interactive chart. EV/EBIT is a ratio that compares a company’s Enterprise Value (EV) to its Earnings Before Interest, Taxes (EBIT), but after Depreciation and Amortization.. The EV/EBIT ratio is a valuation metric used to compare the relative value of different businesses. A low EV/EBIT compared to a stock’s historical average or industry can indicate undervaluation. EV/EBIT takes into account the reinvestment needs of a business (depreciation, amortization).


Highlights and Quick Summary

Current EV/EBIT of Waters Corporation is 25.39 (as of December 30, 2020)
  • EV/EBIT for the quarter ending December 30, 2020 was 25.39 (a 17.19% increase compared to previous quarter)
  • Year-over-year quarterly EV/EBIT increased by 28.83%
  • Annual EV/EBIT for 2020 was 25.39 (a 10.08% increase from previous year)
  • Annual EV/EBIT for 2019 was 23.07 (a 22.45% increase from previous year)
  • Annual EV/EBIT for 2018 was 18.84 (a -11.63% decrease from previous year)
Visit stockrow.com/WAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/EBIT of Waters Corporation

Most recent EV/EBITof WAT including historical data for past 10 years.

Interactive Chart of EV/EBIT of Waters Corporation

Waters Corporation EV/EBIT for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 25.39 21.67 19.91 19.71 25.39
2019 23.07 21.85 21.7 25.19 23.07
2018 18.84 19.18 19.61 20.58 18.84
2017 21.32 20.27 20.94 17.73 21.32
2016 15.86 19.64 17.88 17.51 15.86
2015 17.93 15.84 17.42 17.34 17.93
2014 16.78 14.46 16.05 17.03 16.78
2013 15.33 17.0 16.37 14.83 15.33
2012 14.0 12.78 11.94 14.75 14.0
2011 11.95 12.41 17.1 15.47 11.95
2010 15.41 14.84 14.13 15.41

Business Profile of Waters Corporation

Sector: Healthcare
Industry: Diagnostics & Research
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.